argenex SE $ARGX Stake Lifted by QRG Capital Management Inc.

QRG Capital Management Inc. boosted its stake in argenex SE (NASDAQ:ARGX) by 65.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,530 shares of the company’s stock after buying an additional 607 shares during the period. QRG Capital Management Inc.’s holdings in argenex were worth $1,117,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in ARGX. Abound Wealth Management increased its holdings in shares of argenex by 3,200.0% in the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after acquiring an additional 32 shares during the period. Sound Income Strategies LLC bought a new position in argenex in the 4th quarter worth about $28,000. Ameriflex Group Inc. bought a new position in argenex in the 3rd quarter worth about $32,000. Aventura Private Wealth LLC acquired a new stake in shares of argenex in the fourth quarter valued at approximately $38,000. Finally, Sunbelt Securities Inc. acquired a new stake in shares of argenex in the third quarter valued at approximately $36,000. 60.32% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ARGX. Weiss Ratings raised argenex from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday. Bank of America raised their price target on argenex from $1,016.00 to $1,088.00 and gave the company a “buy” rating in a report on Thursday, July 2nd. Wells Fargo & Company lifted their price objective on shares of argenex from $1,260.00 to $1,291.00 and gave the company an “overweight” rating in a research note on Monday, June 1st. Wedbush reiterated an “outperform” rating and issued a $1,000.00 target price on shares of argenex in a research report on Thursday, June 11th. Finally, Glj Research raised shares of argenex to a “strong-buy” rating in a research note on Friday, April 3rd. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,037.61.

argenex Price Performance

NASDAQ ARGX opened at $915.30 on Thursday. The company’s 50 day simple moving average is $848.98 and its 200 day simple moving average is $812.23. argenex SE has a 12 month low of $538.91 and a 12 month high of $953.58. The company has a market capitalization of $56.92 billion, a P/E ratio of 40.75, a PEG ratio of 1.14 and a beta of 0.45.

argenex (NASDAQ:ARGX) last issued its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. The firm had revenue of $1.31 billion during the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. On average, analysts anticipate that argenex SE will post 26.27 earnings per share for the current year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.